ProKidney (MEX:PROK) FCF Yield % : -63.05 (As of Dec. 14, 2024)

View and export this data going back to 2022. Start your Free Trial

What is ProKidney FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, ProKidney's Trailing 12-Month Free Cash Flow is MXN-2,388.96 Mil, and Market Cap is MXN4,644.85 Mil. Therefore, ProKidney's FCF Yield % for today is -63.05%.

The historical rank and industry rank for ProKidney's FCF Yield % or its related term are showing as below:

MEX:PROK' s FCF Yield % Range Over the Past 10 Years
Min: -141.19 Med: 0 Max: 0
Current: -63.05

MEX:PROK's FCF Yield % is ranked worse than
76.05% of 1507 companies
in the Biotechnology industry
Industry Median: -12.96 vs MEX:PROK: -63.05

ProKidney's FCF Margin % for the quarter that ended in Sep. 2024 was 0.00%.

ProKidney FCF Yield % Historical Data

The historical data trend for ProKidney's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ProKidney FCF Yield % Chart

ProKidney Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

FCF Yield %

-106.74

ProKidney Quarterly Data
	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
FCF Yield %	Get a 7-Day Free Trial											-70.06	-92.62	-147.53	-47.62	-51.96

Competitive Comparison of ProKidney's FCF Yield %

For the Biotechnology subindustry, ProKidney's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ProKidney's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ProKidney's FCF Yield % distribution charts can be found below:

* The bar in red indicates where ProKidney's FCF Yield % falls into.

ProKidney FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

ProKidney's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as

FCF Yield %	=	Free Cash Flow	/	Market Cap
	=	-2109.322	/	1976.0499
	=	-106.74%

ProKidney's annualized FCF Yield % for the quarter that ended in Sep. 2024 is calculated as

FCF Yield %	=	Free Cash Flow	*	Annualized Factor	/	Market Cap
	=	-623.099	*	4	/	4797
	=	-51.96%

ProKidney FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

ProKidney FCF Yield % Related Terms

Thank you for viewing the detailed overview of ProKidney's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

ProKidney Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ProKidney Corp (MEX:PROK) » Definitions » FCF Yield %

Comparable Companies

Traded in Other Exchanges

PROK:USA

Address

2000 Frontis Plaza Boulevard, Suite 250, Winston-Salem, NC, USA, 27103

Website

https://www.prokidney.com

ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's own cells isolated from the patient intended for treatment. Its lead product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's own renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of development program for severe diabetic kidney disease.